Therefore, this study has been performed with the aim of development and validation of the simultaneous quantitative procedure of irbesartan and hydrochlorothiazide in human plasma by LC-MS / MS in accordance with the guidelines of US-FDA and EMA, contributing to the in vivo bioequivalence study of pharmaceuticals containing IRB and HCTZ.